ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph plus Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

被引：0

作者：

Strickland, Stephen ^{[1
]}

Andorsky, David ^{[2
]}

Bruemmendorf, Tim ^{[3
]}

Saussele, Susanne ^{[4
]}

Mahon, Francois-Xavier ^{[5
]}

Pilipovic, Virginia ^{[6
]}

Zhang, Yifan ^{[7
]}

Schuld, Peter ^{[6
]}

Hochhaus, Andreas ^{[8
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] Rocky Mt Canc Ctr, Boulder, CO USA

[3] Uniklin RWTHAachen, Med Klin 4, Aachen, Germany

[4] Univ Klinikum Mannheim, Med Klin Hamatol & Onkol 3, Ilvesheim, Germany

[5] Inst Bergonie, Dept Hematol, Bordeaux, France

[6] Novartis Pharma AG, Basel, Switzerland

[7] Novartis Pharmaceut, E Hanover, NJ USA

[8] Univ Klinukum Jena, Jena, Germany

来源：

关键词：

asciminib; CML; TKI; nilotinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-590

引用

页码：S349 / S350

页数：2